Jazz Pharmaceuticals Ireland Limited

Second Tris Pharma complaint filed after Tris's Jan 2026 notices of 505(b)(2) NDAs for Xyrem/Xywav generics. The narrative lists it among '306-family actions, though only 2:26-cv-01739 is expressly noted as identifying the '306 patent.

Most recent confirmed '306-family action. Status not confirmed.

Xyrem/Xywav action against Teva Pharmaceuticals. Status not confirmed.

First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.

Jazz-side Delaware action in the Avadel–Jazz once-nightly sodium oxybate dispute. The '986 patent appeared on the patent lists in connection with Avadel's counterclaims and inequitable-conduct/derivation allegations concerning Flamel's '321 application and Jazz's '079/'782 patents. The case was resolved by the October 2025 settlement and dismissed with prejudice on 2025-10-27.

Complaint expressly lists the '306 patent among the patents-in-suit. Status not confirmed.

Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.

Lupin action consolidated into the Jazz v. Amneal consolidated litigation, 2:13-cv-00391.